Positive quarterly momentum maintained and well on track to meet full year
management's expectations  

Benchmark (LSE: BMK), the aquaculture biotechnology company, announces its
unaudited interim results for the six months ended 31 March 2024 (the "Period"
or "H1 FY24"). The Company also announces its unaudited results for the three
months ended 31 March 2024 ("Q2 FY24") in compliance with the terms of its
unsecured Green bond. 
Financial Highlights
o	Q2 FY24 positive momentum in Genetics and Advanced Nutrition partially offset
by Health and forex headwinds
o	Q2 FY24 revenues of £39.8m were 10% below Q2 FY23 (-3% CER) driven by a strong
performance in Genetics and Advanced Nutrition, offset by Health 
	Genetics revenues were £13.2m (Q2 FY23: £12.9m) up 7% CER reflecting a solid
performance in the core business and good progress in our growth vectors,
particularly Chile 
	Advanced Nutrition revenues were £21.1m (Q2 FY23: £22.6m) up 3% CER reflecting
the success of our strategy to adapt to difficult shrimp markets
	Health revenues of £5.4m (Q2 FY23: £8.7m) were down 35% CER